soul trial oral semaglutide cardiovascular outcomes results 2024 Effect of on in Type 2 Diabetes by Extent of Vascular Disease Novo Nordisk's Semaglutide lowers MACE

Key takeaways Both Foundayo and the Wegovy pill are once-daily oral GLP-1 receptor agonists approved for obesity and overweight with comorbidities

Reduced Gastrointestinal Side Effects: Biocare contains bioactive anti-nausea compounds, GutGard for daily digestive health, and PepZinGI to help protect the stomach lining

Major population health real-world studies such as SCoMIS, which examines the use of Wegovy in the Scottish population will read-out by 2029, and SURMOUNT-REAL will provide definitive insights into whether use of Obesity Medicines brings healthcare system benefits in the form of, for example, reduced cardiovascular events, diabetes or disability, and may also provide data on wider socio-economic benefits, such as reduced unemployment

Our guide explains the process, what to expect, and the support you'll receive from PrivateDoc

the GLP-1 agonist class transition from injectable specialty drugs to mainstream Type-2 first-line therapy, compressing treatment timelines

doi: 10.1016/j.neuroscience.2011.06.031 48 RomanMIrwinMR